Announced Date: 2025-08-26 (August 26, 2025)
Asset Name: FXS6837 （Other code: XH-S003）
Licensor: Fosun Pharma and Fosun Pharma Industrial. (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) (Headquarter，Shanghai, China)
Licensee (Buyer): Sitala（Sitala Bio Ltd，UK）
.
Asset Target: Undisclosed Immune regulation disease target
[CninMed surmise：Complement Factor B (CFB)，WO2022143940]
Asset Modality: Small Molecule
Current Stage: Phase II, China (IgA, PNH)
Scope of Authority:
Forsun has granted Sitala an exclusive license to develop, manufacture, and commercialize FXS6837 outside Great China
.
Deal Detail:
Upfront payment of $25 million;
Development and regulatory milestone payments up to $165 million;
Sales milestone payments of up to $480 million;
Total up to $670 million.
Additional royalties based on net sales in the licensed territories.
Additionally, Fosun may acquire shares of Sitala valued at $5 million at zero consideration.
.
